이뮤논(IMNN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.40 (+1.45%), 시가총액 $0.01B, 52주 최저~최고 $2.49 ~ $32.74.
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCi
이뮤논의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이뮤논의 현재 주가는 $1.40 (+1.45%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이뮤논의 시가총액은 약 $0.01B입니다.
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherap